2.2 Enzyme Inhibition & Kinetics Modifications

Key Takeaways

  • Competitive inhibitors bind exclusively to the free enzyme's active site, increasing apparent Km while leaving Vmax completely unchanged because high substrate concentration overcomes inhibition.
  • Uncompetitive inhibitors bind selectively to the ES complex at an allosteric site, decreasing apparent Km and Vmax by the exact same proportion, producing parallel lines on a Lineweaver-Burk plot.
  • Pure noncompetitive inhibitors bind free enzyme and ES complex with equal affinity, decreasing Vmax while leaving Km unchanged, resulting in a common x-intercept (-1/Km) on a Lineweaver-Burk plot.
  • Mixed inhibitors bind free enzyme and ES complex with unequal affinities, decreasing Vmax while either increasing apparent Km (if binding E preferentially) or decreasing apparent Km (if binding ES preferentially).
  • Irreversible inhibitors covalently modify active site functional groups or act as suicide substrates, permanently destroying enzyme activity and reducing functional [E]T.
Last updated: August 2026

Classification of Enzyme Inhibitors

Enzyme inhibition is a fundamental regulatory mechanism in metabolic pathways and represents the primary mechanism of action for a vast proportion of modern pharmaceuticals. Inhibitors are chemical agents that diminish the rate of an enzymatic reaction by interfering with substrate binding, catalytic conversion, or both.

Inhibitors are broadly categorized into two major classes based on the nature of their binding:

  1. Reversible Inhibitors: Bind to enzymes through non-covalent interactions (hydrogen bonds, ionic interactions, hydrophobic effects, and van der Waals forces). Reversible inhibition establishes a rapid equilibrium, allowing the inhibitor to dissociate from the enzyme when its concentration declines.
  2. Irreversible Inhibitors: Form covalent bonds with essential active site amino acid side chains or dissociate extremely slowly, permanently inactivating the enzyme molecule.

Reversible enzyme inhibition is subdivided into four distinct kinetic mechanisms based on whether the inhibitor binds to the free enzyme ($E$), the enzyme-substrate complex ($ES$), or both: competitive, uncompetitive, noncompetitive, and mixed inhibition.


Competitive Inhibition: Active Site Competition

A competitive inhibitor ($I$) is a structural analogue of the natural substrate that competes directly with the substrate for binding to the free enzyme's active site. Because the active site can bind either the substrate or the inhibitor, but never both simultaneously, the formation of an enzyme-inhibitor complex ($EI$) and an enzyme-substrate complex ($ES$) are mutually exclusive:

E+IEIE + I \rightleftharpoons EI

The equilibrium dissociation constant for the competitive inhibitor is designated $K_i = [E][I]/[EI]$.

Kinetic Effects on Km and Vmax

  • Apparent $K_m$ ($K_{m,\text{app}}$) Increases: Because the inhibitor ties up a fraction of free enzyme in an inactive $EI$ complex, a higher substrate concentration is required to achieve half-maximal velocity. The apparent $K_m$ increases by a factor of $\alpha = 1 + [I]/K_i$, such that $K_{m,\text{app}} = \alpha K_m$.
  • $V_{\text{max}}$ Remains Unchanged: Competitive inhibition can be completely overcome by adding an overwhelming excess of substrate ($[S] \rightarrow \infty$). Under high substrate concentrations, substrate outcompetes the inhibitor for active site binding, forcing all enzyme into the $ES$ complex. Thus, $V_{\text{max}}$ is fully preserved.

Lineweaver-Burk Plot Characteristics

On a double-reciprocal plot ($1/v_0$ vs $1/[S]$):

  • Lines in the presence and absence of a competitive inhibitor intersect directly on the Y-axis at $1/V_{\text{max}}$, confirming that $V_{\text{max}}$ is unchanged.
  • The slope ($K_m/V_{\text{max}}$) increases by the factor $\alpha$.
  • The X-intercept ($-1/K_{m,\text{app}}$) shifts closer to the origin (to the right), reflecting the increase in apparent $K_m$.

High-Yield MCAT Clinical Example: Statins (e.g., atorvastatin) are competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Methotrexate competitively inhibits dihydrofolate reductase (DHFR) by mimicking folate.


Uncompetitive Inhibition: ES Complex Binding

An uncompetitive inhibitor does not bind to the free enzyme ($E$). Instead, it binds exclusively to the enzyme-substrate complex ($ES$) at an allosteric site that is structurally formed or exposed only after the substrate binds to the active site:

ES+IESIES + I \rightleftharpoons ESI

The ternary $ESI$ complex is catalytically inactive and cannot proceed to yield product. The equilibrium dissociation constant is designated $K_i' = [ES][I]/[ESI]$.

Kinetic Effects on Km and Vmax

  • $V_{\text{max}}$ Decreases: Binding of the inhibitor removes functional $ES$ complexes from the catalytic pool. Because $ESI$ cannot form product, maximal velocity drops to an apparent value $V_{\text{max,\text{app}}} = V_{\text{max}} / \alpha'$, where $\alpha' = 1 + [I]/K_i'$. Crucially, because the inhibitor binds a state that substrate cannot outcompete, increasing substrate concentration cannot restore $V_{\text{max}}$.
  • Apparent $K_m$ ($K_{m,\text{app}}$) Decreases: According to Le Chatelier's principle, binding of the inhibitor to $ES$ depletes the $ES$ concentration, pulling the $E + S \rightleftharpoons ES$ equilibrium to the right. This apparent increase in the enzyme's affinity for substrate reduces the concentration of substrate required to reach half of the new $V_{\text{max}}$, decreasing apparent $K_m$ to $K_{m,\text{app}} = K_m / \alpha'$.

Lineweaver-Burk Plot Characteristics

Because both $K_m$ and $V_{\text{max}}$ are decreased by the exact same proportional factor ($\alpha'$), the ratio of $K_m$ to $V_{\text{max}}$ (the slope of the line, $K_m/V_{\text{max}}$) remains completely unchanged. Consequently, double-reciprocal plots of uncompetitive inhibition display a series of parallel lines that shift upward (higher y-intercept) and leftward (more negative x-intercept) as inhibitor concentration increases.


Noncompetitive Inhibition: Equal Affinity for Free E and ES

A pure noncompetitive inhibitor is a special case of mixed inhibition in which the inhibitor binds to an allosteric site away from the active site with equal binding affinity for both the free enzyme ($E$) and the enzyme-substrate complex ($ES$), meaning $K_i = K_i'$ ($\alpha = \alpha'$):

E+IEIandES+IESIE + I \rightleftharpoons EI \quad \text{and} \quad ES + I \rightleftharpoons ESI

Because the active site and allosteric site operate independently, substrate binding is not obstructed by inhibitor binding, but the resulting $EI$ or $ESI$ complexes are catalytically dead.

Kinetic Effects on Km and Vmax

  • $V_{\text{max}}$ Decreases: Noncompetitive inhibition effectively reduces the concentration of functionally active enzyme present in solution. $V_{\text{max}}$ decreases to $V_{\text{max,\text{app}}} = V_{\text{max}} / \alpha$.
  • $K_m$ Remains Unchanged: Because the inhibitor binds $E$ and $ES$ with equal affinity, it does not alter the relative binding equilibrium between free enzyme and substrate. Therefore, the substrate concentration required to achieve half of $V_{\text{max,\text{app}}}$ is identical to the original $K_m$.

Lineweaver-Burk Plot Characteristics

On a double-reciprocal plot:

  • Lines in the presence of varying inhibitor concentrations intersect at a single point directly on the X-axis at $-1/K_m$.
  • The Y-intercept ($1/V_{\text{max,\text{app}}}$) moves upward as inhibitor concentration increases, while the slope increases.

Mixed Inhibition: Unequal Affinity for E and ES

Mixed inhibition occurs when an inhibitor binds to an allosteric site on both the free enzyme ($E$) and the enzyme-substrate complex ($ES$), but exhibits different binding affinities for the two forms ($K_i \neq K_i'$, or $\alpha \neq \alpha'$).

Kinetic Effects on Km and Vmax

  • $V_{\text{max}}$ Always Decreases: In all cases of mixed inhibition, functional catalytic capacity is compromised, causing $V_{\text{max}}$ to decrease to $V_{\text{max,\text{app}}} = V_{\text{max}} / \alpha'$.
  • $K_m$ Shift Depends on Binding Preference:
    1. If the inhibitor prefers binding to the free enzyme ($K_i < K_i'$, or $\alpha > \alpha'$), free enzyme is predominantly sequestered into $EI$. This hinders substrate binding, causing apparent $K_m$ to increase ($K_{m,\text{app}} > K_m$).
    2. If the inhibitor prefers binding to the $ES$ complex ($K_i > K_i'$, or $\alpha < \alpha'$), $ES$ is sequestered into $ESI$, pulling substrate binding forward and causing apparent $K_m$ to decrease ($K_{m,\text{app}} < K_m$).

Lineweaver-Burk Plot Characteristics

Double-reciprocal lines for mixed inhibitors intersect at a point to the left of the Y-axis: above the X-axis if $K_i < K_i'$ (increased $K_m$), or below the X-axis if $K_i > K_i'$ (decreased $K_m$).


Summary of Reversible Inhibition Parameters

Inhibition TypeBinding SiteApparent $K_m$Apparent $V_{\text{max}}$Lineweaver-Burk Plot Feature
CompetitiveActive site (binds $E$ only)Increases ($\alpha K_m$)UnchangedIntersect on Y-axis ($1/V_{\text{max}}$)
UncompetitiveAllosteric site (binds $ES$ only)Decreases ($K_m / \alpha'$)Decreases ($V_{\text{max}} / \alpha'$)Parallel lines (slope $K_m/V_{\text{max}}$ constant)
NoncompetitiveAllosteric site (equal $E$ & $ES$)UnchangedDecreases ($V_{\text{max}} / \alpha$)Intersect on X-axis ($-1/K_m$)
Mixed ($E > ES$)Allosteric site ($K_i < K_i'$)IncreasesDecreasesIntersect left of Y-axis, above X-axis
Mixed ($ES > E$)Allosteric site ($K_i > K_i'$)DecreasesDecreasesIntersect left of Y-axis, below X-axis

Irreversible Inhibition & Suicide Substrates

Unlike reversible inhibitors, irreversible inhibitors permanently disable an enzyme by forming stable covalent bonds with active site catalytic residues or causing irreversible structural denaturation. Kinetic evaluation of irreversible inhibition shows a progressive, time-dependent reduction in total active enzyme concentration ($[E]T$). Consequently, irreversible inhibition lowers $V{\text{max}}$ in a manner that cannot be reversed by dialysis or substrate competition.

Mechanism-Based (Suicide) Inhibitors

A highly sophisticated class of irreversible inhibitors is suicide inhibitors (or mechanism-based inactivators). A suicide inhibitor is an unreactive substrate analogue that binds to the enzyme's active site as a normal substrate. The enzyme initiates its normal catalytic mechanism on the inhibitor, converting it into a highly reactive intermediate. Before leaving the active site, this intermediate forms an unbreakable covalent bond with a catalytic amino acid side chain, permanently trapping and killing the enzyme.

High-Yield MCAT Examples:

  1. Penicillin: Irreversibly inhibits bacterial glycopeptide transpeptidase by forming a covalent acyl-enzyme complex with an active-site serine residue, blocking bacterial cell wall synthesis.
  2. Aspirin (Acetylsalicylic Acid): Irreversibly acetylates Ser-530 near the active site of cyclooxygenase (COX-1 and COX-2), inhibiting thromboxane A2 synthesis in platelets for their entire 8-10 day lifespan.
  3. Organophosphates (e.g., Sarin, Malathion): Irreversibly phosphorylate the catalytic serine residue of acetylcholinesterase, preventing acetylcholine breakdown at neuromuscular junctions.
Loading diagram...
Lineweaver-Burk Graphical Signatures of Reversible Enzyme Inhibition
Test Your Knowledge

A researcher adds a novel drug to an enzymatic assay and observes that the apparent Km increases from 2.0 mM to 6.0 mM, while Vmax remains fixed at 200 umol/min. What type of inhibition is occurring?

A
B
C
D
Test Your Knowledge

An enzyme assay conducted in the presence of an inhibitor yields double-reciprocal Lineweaver-Burk lines that are strictly parallel to the uninhibited control line. Which structural mechanism accounts for this kinetic pattern?

A
B
C
D
Test Your Knowledge

How does a pure noncompetitive inhibitor alter the Lineweaver-Burk plot relative to an uninhibited reaction?

A
B
C
D
Test Your Knowledge

Which statement correctly describes the mechanism of action of aspirin as an enzyme inhibitor?

A
B
C
D